Clinical flaws in the breast cancer ADAM10 and atrial fibrillation study

Clicks: 1
ID: 319970
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #284 of 310 articles by views in european heart journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 310 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This commentary refers to ‘Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation’, by G. Xue et al., https://doi.org/10.1093/eurheartj/ehag147 We read with interest the study by Xue et al.1 reporting that breast cancer (Bc)-derived soluble ADAM10 promotes atrial fibrosis and fibrillation. While the findings are intriguing, two critical flaws undermine the causal inferences. First, the clinical comparison of atrial fibrillation (AF) prevalence between pre-treatment Bc patients and controls suffers from detection bias. Bc patients underwent electrocardiography (ECG) and Holter monitoring as part of pre-therapy evaluation, whereas controls received only a single ECG during a routine health check-up (Methods). This differential surveillance intensity inevitably inflates AF detection in the Bc group, especially for paroxysmal AF. The authors did not report Holter utilization rates nor adjust for monitoring duration. With an AF prevalence of only .90% in controls—far below the expected 2%–4% for age-matched females—the observed seven-fold higher risk is likely an artefact of ascertainment bias rather than a true tumour effect.
Reference Key
openalex_W7167604741 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lingfeng Tang, Fangfang Li, Maoshan Chen
Journal european heart journal
Year 2026
DOI
10.1093/eurheartj/ehag491
URL
https://doi.org/10.1093/eurheartj/ehag491
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.